38
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      How We Read Oncologic FDG PET/CT

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          18F-fluorodeoxyglucose (FDG) PET/CT is a pivotal imaging modality for cancer imaging, assisting diagnosis, staging of patients with newly diagnosed malignancy, restaging following therapy and surveillance. Interpretation requires integration of the metabolic and anatomic findings provided by the PET and CT components which transcend the knowledge base isolated in the worlds of nuclear medicine and radiology, respectively. In the manuscript we detail our approach to reviewing and reporting a PET/CT study using the most commonly used radiotracer, FDG. This encompasses how we display, threshold intensity of images and sequence our review, which are essential for accurate interpretation. For interpretation, it is important to be aware of benign variants that demonstrate high glycolytic activity, and pathologic lesions which may not be FDG-avid, and understand the physiologic and biochemical basis of these findings. Whilst FDG PET/CT performs well in the conventional imaging paradigm of identifying, counting and measuring tumour extent, a key paradigm change is its ability to non-invasively measure glycolytic metabolism. Integrating this “metabolic signature” into interpretation enables improved accuracy and characterisation of disease providing important prognostic information that may confer a high management impact and enable better personalised patient care.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients

          Purpose Point-spread function (PSF) or PSF + time-of-flight (TOF) reconstruction may improve lesion detection in oncologic PET, but can alter quantitation resulting in variable standardized uptake values (SUVs) between different PET systems. This study aims to validate a proprietary software tool (EQ.PET) to harmonize SUVs across different PET systems independent of the reconstruction algorithm used. Methods NEMA NU2 phantom data were used to calculate the appropriate filter for each PSF or PSF+TOF reconstruction from three different PET systems, in order to obtain EANM compliant recovery coefficients. PET data from 517 oncology patients were reconstructed with a PSF or PSF+TOF reconstruction for optimal tumour detection and an ordered subset expectation maximization (OSEM3D) reconstruction known to fulfil EANM guidelines. Post-reconstruction, the proprietary filter was applied to the PSF or PSF+TOF data (PSFEQ or PSF+TOFEQ). SUVs for PSF or PSF+TOF and PSFEQ or PSF+TOFEQ were compared to SUVs for the OSEM3D reconstruction. The impact of potential confounders on the EQ.PET methodology including lesion and patient characteristics was studied, as was the adherence to imaging guidelines. Results For the 1380 tumour lesions studied, Bland-Altman analysis showed a mean ratio between PSF or PSF+TOF and OSEM3D of 1.46 (95 %CI: 0.86–2.06) and 1.23 (95 %CI: 0.95–1.51) for SUVmax and SUVpeak, respectively. Application of the proprietary filter improved these ratios to 1.02 (95 %CI: 0.88–1.16) and 1.04 (95 %CI: 0.92–1.17) for SUVmax and SUVpeak, respectively. The influence of the different confounding factors studied (lesion size, location, radial offset and patient’s BMI) was less than 5 %. Adherence to the European Association of Nuclear Medicine (EANM) guidelines for tumour imaging was good. Conclusion These data indicate that it is not necessary to sacrifice the superior lesion detection and image quality achieved by newer reconstruction techniques in the quest for harmonizing quantitative comparability between PET systems. Electronic supplementary material The online version of this article (doi:10.1007/s00259-015-3128-0) contains supplementary material, which is available to authorized users.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The role of PET in monitoring therapy

            Positron emission tomography (PET) is being increasingly used for the evaluation of patients with known or suspected cancer at all phases of the management process from diagnosis, through staging to follow-up after treatment. The role of PET in therapeutic monitoring is expanding rapidly due to its ability to provide earlier and more robust identification of non-responders than provided by conventional non-invasive imaging approaches. PET can thereby potentially provide important benefits to the individual patient by allowing an earlier change to alternative treatments that may be more efficacious or by avoiding the unnecessary toxicity related to ineffective therapy. As therapies become ever more expensive, this could also produce cost savings because of earlier termination of ineffective treatment. Conversely, PET may demonstrate important biological effects despite a lack of apparent morphological response and therefore prevent premature withdrawal of effective therapies. Globally, the vast majority of therapeutic monitoring studies use the glucose analogue, fluorine-18 fluorodeoxyglucose (FDG) but new tracers such as fluorine-18 fluorothymidine (FLT) also offer promise for this application. In this review, the potential benefits and limitations of FDG PET are discussed along with suggestions regarding the most practical methodologies for response evaluation using this modality.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Impact of medication discontinuation on increased intestinal FDG accumulation in diabetic patients treated with metformin.

              We evaluated the impact of stopping medication for 2 days on reductions in the high intestinal FDG uptake induced by metformin.
                Bookmark

                Author and article information

                Contributors
                +613 8559 5510 , michael.hofman@petermac.org
                +613 8559 5510 , rod.hicks@petermac.org
                Journal
                Cancer Imaging
                Cancer Imaging
                Cancer Imaging
                BioMed Central (London )
                1740-5025
                1470-7330
                18 October 2016
                18 October 2016
                2016
                : 16
                : 35
                Affiliations
                [1 ]Centre for Molecular Imaging, Dept of Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, 3000 Australia
                [2 ]Sir Peter MacCallum Department of Oncology and Department of Medicine, University of Melbourne, Melbourne, Australia
                Author information
                http://orcid.org/0000-0001-8622-159X
                Article
                91
                10.1186/s40644-016-0091-3
                5067887
                27756360
                42cc02ac-fce2-42ad-a5c5-6180428faeda
                © The Author(s). 2016

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 3 August 2016
                : 20 September 2016
                Categories
                Review
                Custom metadata
                © The Author(s) 2016

                fluorodeoxyglucose fdg,positron-emission tomography,radiology,medical oncology

                Comments

                Comment on this article